Serotonin agonist-intranasal - NastechAlternative Names: Intranasal serotonin agonist - Nastech; Intranasal triptan - Nastech; Triptan-intranasal - Nastech
Latest Information Update: 09 Jun 2004
At a glance
- Originator Nastech Pharmaceutical Company
- Developer Marina Biotech
- Class Tryptamines
- Mechanism of Action Serotonin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Migraine
Most Recent Events
- 09 Jun 2004 Suspended - Phase-I for Migraine in USA (Intranasal)
- 07 May 2002 Phase-I clinical trials in Migraine in USA (Intranasal)